Rapalogs and mTOR inhibitors as anti-aging therapeutics
Open accessThe DOI matches its Crossref record; 133 of the 133 references it cites were found in a registry or an index.
Abstract
Rapamycin, an inhibitor of mechanistic target of rapamycin (mTOR), has the strongest experimental support to date as a potential anti-aging therapeutic in mammals. Unlike many other compounds that have been claimed to influence longevity, rapamycin has been repeatedly tested in long-lived, genetically heterogeneous mice, in which it extends both mean and maximum life spans. However, the mechanism that accounts for these effects is far from clear, and a growing list of side effects make it doubtful that rapamycin would ultimately be beneficial in humans. This Review discusses the prospects for developing newer, safer anti-aging therapies based on analogs of rapamycin (termed rapalogs) or other approaches targeting mTOR signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Rapamycin and its analogs (so-called ‘rapalogs’) suppress the SASP by inhibiting mTOR and appear to extend healthspan and lifespan in mice105,108,109.”
From Cellular senescence and senolytics: the path to the clinic (2022) · cites this paper as [105]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In fact, reviewing the effects of other interventions like rapalogs and sirtuins also shows that they may be impacting many of the similar hallmarks of aging (Lamming et al. 2013, Grabowska et al. 2017).”
From Benefits of Metformin in Attenuating the Hallmarks of Aging (2020) · cites this paper as Lamming et al. 2013
The cited source says what the claim attributes to it.
In the citing paper
“Many of the side effects of rapamycin, which include immunosuppression, hyperlipidemia and hyperglycemia, have raised concerns about the feasibility of using rapamycin to promote healthy longevity in humans and slowed clinical evaluation of mTOR inhibitors for diseases of aging 26.”
From Targeting the biology of aging with mTOR inhibitors (2023) · cites this paper as [26]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“SASP inhibitors (senomorphics) can directly or indirectly attenuate the SASP of senescent cells by inhibiting transcription factor nuclear factor (NF)-κB, the JAK-STAT signal transduction pathway, the serine/threonine protein kinase mTOR, mitochondrial complex-1-related or 4-related targets, or other pathways involved in the induction and maintenance of the SASP103–106.”
From Cellular senescence and senolytics: the path to the clinic (2022) · cites this paper as [105]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“no senolytic compounds developed to date are able to eliminate all types of senescent cells; further they retain a low level of toxicity to young normal cells (Lamming et al., 2013).”
From Single senescent cell sequencing reveals heterogeneity in senescent cells induced by telomere erosion (2019) · cites this paper as Lamming et al., 2013
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1
Kim, J., Kundu, M., Viollet, B., & Guan, K.-L. (2011) · Nature Cell Biology · doi:10.1038/ncb2152 · Cited by 7,227 · cited 2×
“the autophagy-initiating kinase ULK1 (46).”
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652 · cited 14×
“We might therefore expect other compounds that activate AMPK to specifically inhibit mTORC1 activity.”
BackgroundInfluentialAMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint
Gwinn, D. M., Shackelford, D. B., Egan, D. F., Mihaylova, M. M., Mery, A., Vasquez, D. S., Turk, B. E., & Shaw, R. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.03.003 · Cited by 3,849 · cited 1×
“phorylation of TSC2 and the inhibitory phosphorylation of raptor, an essential component of mTORC1 (92, 93).”
BackgroundNathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
Harrison, D. E., Strong, R., Sharp, Z. D., Nelson, J. F., Astle, C. M., Flurkey, K., Nadon, N. L., Wilkinson, J. E., Frenkel, K., Carter, C. S., et al. (2009) · Nature · doi:10.1038/nature08221 · Cited by 3,766
Sancak, Y., Bar-Peled, L., Zoncu, R., Markhard, A. L., Nada, S., & Sabatini, D. M. (2010) · Cell · doi:10.1016/j.cell.2010.02.024 · Cited by 2,464 · cited 1×
“The Rag proteins activate mTORC1 by localizing mTORC1 to the lysosome via interaction with the ragulator complex (110).”
BackgroundSelf-citationProlonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365 · cited 1×
“This effect was first observed in certain cultured cell lines (73), and we have recently shown that it also occurs in vivo in multiple tissues including liver, muscle, and adipose (see Figure 2).”
BackgroundSelf-citationLaplante, M., & Sabatini, D. M. (2009) · Journal of Cell Science · doi:10.1242/jcs.051011 · Cited by 2,170 · cited 1×
“through a wide variety of signaling mechanisms and have roles in many aspects of physiology, which have been reviewed in depth (9).”
BackgroundSelf-citationFranceschi, C., Capri, M., Monti, D., Giunta, S., Olivieri, F., Sevini, F., Panourgia, M. P., Invidia, L., Celani, L., Scurti, M., et al. (2007) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2006.11.016 · Cited by 2,087 · cited 1×
“Chronic, low-grade inflammation is a feature of aging, and almost every chronic disease has an inflammatory component (71).”
BackgroundA mammalian protein targeted by G1-arresting rapamycin–receptor complex
Brown, E. J., Albers, M. W., Bum Shin, T., ichikawa, K., Keith, C. T., Lane, W. S., & Schreiber, S. L. (1994) · Nature · doi:10.1038/369756a0 · Cited by 2,053 · cited 2×
“Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3yl)benzo[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer.”
BackgroundTargets for Cell Cycle Arrest by the Immunosuppressant Rapamycin in Yeast
Heitman, J., Movva, N. R., & Hall, M. N. (1991) · Science · doi:10.1126/science.1715094 · Cited by 2,006 · cited 1×
“Two additional proteins required for its effects in yeast were identified in a genetic screen in 1991 and termed target of rapamycin 1 (TOR1) and TOR2 (5).”
BackgroundThoreen, C. C., Kang, S. A., Chang, J. W., Liu, Q., Zhang, J., Gao, Y., Reichling, L. J., Sim, T., Sabatini, D. M., & Gray, N. S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m900301200 · Cited by 1,803 · cited 1×
“in particular have revealed important but previously unknown biological mechanisms, including rapamycin-resistant functions of mTORC1 (85, 86).”
BackgroundSelf-citationVÉZINA, C., KUDELSKI, A., & SEHGAL, S. N. (1975) · The Journal of Antibiotics · doi:10.7164/antibiotics.28.721 · Cited by 1,687 · cited 1×
“A brief history of rapamycin and mechanistic target of rapamycin Rapamycin was discovered in the soil of Easter Island as a compound produced by Streptomyces hygroscopicus that was capable of inhibiting the proliferation of the yeast Candida albicans but did not affect the growth of bacteria (1).”
BackgroundmTOR regulates memory CD8 T-cell differentiation
Araki, K., Turner, A. P., Shaffer, V. O., Gangappa, S., Keller, S. A., Bachmann, M. F., Larsen, C. P., & Ahmed, R. (2009) · Nature · doi:10.1038/nature08155 · Cited by 1,575 · cited 1×
“Studies have found that rapamycin boosts the function of the immune system against certain pathogens (80), but human”
BackgroundSabatini, D. M., Erdjument-Bromage, H., Lui, M., Tempst, P., & Snyder, S. H. (1994) · Cell · doi:10.1016/0092-8674(94)90570-3 · Cited by 1,509
Self-citationRothwell, P. M., Fowkes, F. G. R., Belch, J. F., Ogawa, H., Warlow, C. P., & Meade, T. W. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62110-1 · Cited by 1,497 · cited 1×
“decrease cancer-related and all-cause mortality in humans (96).”
BackgroundA unifying model for mTORC1-mediated regulation of mRNA translation
Thoreen, C. C., Chantranupong, L., Keys, H. R., Wang, T., Gray, N. S., & Sabatini, D. M. (2012) · Nature · doi:10.1038/nature11083 · Cited by 1,477 · cited 2×
“complete loss of mTOR function has a major effect on general translation, rapamycin has a more subtle effect, most likely because a subset of the functions of 4E-BP is rapamycin resistant (42, 43).”
BackgroundSelf-citationGuertin, D. A., Stevens, D. M., Thoreen, C. C., Burds, A. A., Kalaany, N. Y., Moffat, J., Brown, M., Fitzgerald, K. J., & Sabatini, D. M. (2006) · Developmental Cell · doi:10.1016/j.devcel.2006.10.007 · Cited by 1,415 · cited 1×
“Genetic inhibition of mTOR signaling in mammals is a delicate matter, as the mTOR protein kinase, raptor, rictor, and mLST8 are all essential for development (15).”
BackgroundSelf-citationRegulation of lifespan in Drosophila by modulation of genes in the TOR signaling pathway
Kapahi, P., Zid, B. M., Harper, T., Koslover, D., Sapin, V., & Benzer, S. (2004) · Current Biology · doi:10.1016/j.cub.2004.03.059 · Cited by 1,293
Regulation of Yeast Replicative Life Span by TOR and Sch9 in Response to Nutrients
Kaeberlein, M., Powers, R. W., Steffen, K. K., Westman, E. A., Hu, D., Dang, N., Kerr, E. O., Kirkland, K. T., Fields, S., & Kennedy, B. K. (2005) · Science · doi:10.1126/science.1115535 · Cited by 1,293
Nathan, D. M., Buse, J. B., Davidson, M. B., Heine, R. J., Holman, R. R., Sherwin, R., & Zinman, B. (2006) · Diabetes Care · doi:10.2337/dc06-9912 · Cited by 1,203
Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from Longevity
Lamming, D. W., Ye, L., Katajisto, P., Goncalves, M. D., Saitoh, M., Stevens, D. M., Davis, J. G., Salmon, A. B., Richardson, A., Ahima, R. S., et al. (2012) · Science · doi:10.1126/science.1215135 · Cited by 1,199 · cited 2×
“Recently, we demonstrated that female Mtor+/–Mlst8+/– mice have reduced mTORC1 activity and increased longevity, similar to the phenotype reported by Selman and colleagues for mice that lack S6K1, one of the principal substrates of mTORC1 (16, 17).”
BackgroundSelf-citationArcaro, A., & Wymann, M. P. (1993) · Biochemical Journal · doi:10.1042/bj2960297 · Cited by 1,140
Ribosomal Protein S6 Kinase 1 Signaling Regulates Mammalian Life Span
Selman, C., Tullet, J. M. A., Wieser, D., Irvine, E., Lingard, S. J., Choudhury, A. I., Claret, M., Al-Qassab, H., Carmignac, D., Ramadani, F., et al. (2009) · Science · doi:10.1126/science.1177221 · Cited by 1,120 · cited 2×
“Recently, we demonstrated that female Mtor+/–Mlst8+/– mice have reduced mTORC1 activity and increased longevity, similar to the phenotype reported by Selman and colleagues for mice that lack S6K1, one of the principal substrates of mTORC1 (16, 17).”
BackgroundPten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells
Yilmaz, Ö. H., Valdez, R., Theisen, B. K., Guo, W., Ferguson, D. O., Wu, H., & Morrison, S. J. (2006) · Nature · doi:10.1038/nature04703 · Cited by 1,113 · cited 1×
“rapamycin depletes leukemia-initiating cells and inhibits both the self-renewal and differentiation capacities of stem cells derived from infantile hemangioma, suggesting a protective effect against cancer stem cells (61, 70).”
BackgroundEfficacy and safety of sirolimus in lymphangioleiomyomatosis
McCormack, F. X., Inoue, Y., Moss, J., Singer, L. G., Strange, C., Nakata, K., Barker, A. F., Chapman, J. T., Brantly, M. L., Stocks, J. M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1100391 · Cited by 1,099
Hsu, P. P., Kang, S. A., Rameseder, J., Zhang, Y., Ottina, K. A., Lim, D., Peterson, T. R., Choi, Y., Gray, N. S., Yaffe, M. B., et al. (2011) · Science · doi:10.1126/science.1199498 · Cited by 1,084
Self-citationActive-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
Feldman, M. E., Apsel, B., Uotila, A., Loewith, R., Knight, Z. A., Ruggero, D., & Shokat, K. M. (2009) · PLoS Biology · doi:10.1371/journal.pbio.1000038 · Cited by 1,082
Influence of TOR kinase on lifespan in C. elegans
Vellai, T., Takacs-Vellai, K., Zhang, Y., Kovacs, A. L., Orosz, L., & Müller, F. (2003) · Nature · doi:10.1038/426620a · Cited by 1,057 · cited 2×
“Connecting mTOR signaling to aging A role for TOR signaling in aging was first revealed in 2003, when Vellai and colleagues showed that RNAi against let-363/ CeTor significantly extended the life span of Caenorhabditis elegans and functioned independently from daf-16, a FOXO homolog that had previously been shown to i…”
BackgroundMechanisms of Life Span Extension by Rapamycin in the Fruit Fly Drosophila Melanogaster
Bjedov, I., Toivonen, J. M., Kerr, F., Slack, C., Jacobson, J., Foley, A., & Partridge, L. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2009.11.010 · Cited by 1,057
Spilman, P., Podlutskaya, N., Hart, M. J., Debnath, J., Gorostiza, O., Bredesen, D., Richardson, A., Strong, R., & Galvan, V. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009979 · Cited by 1,033
Extension of Chronological Life Span in Yeast by Decreased TOR Pathway Signaling
Powers, R. W., Kaeberlein, M., Caldwell, S. D., Kennedy, B. K., & Fields, S. (2006) · Genes & Development · doi:10.1101/gad.1381406 · Cited by 982
Rapamycin suppresses 5′TOP mRNA translation through inhibition of p70s6k
Jefferies, H. B. J., Fumagalli, S., Dennis, P. B., Reinhard, C., Pearson, R. B., & Thomas, G. (1997) · The EMBO Journal · doi:10.1093/emboj/16.12.3693 · Cited by 934 · cited 1×
“org Volume 123 Number 3 March 2013 983 pyrimidine motifs, suggesting a potential role for these genes in longevity (43, 44).”
BackgroundDowling, R. J. O., Zakikhani, M., Fantus, I. G., Pollak, M., & Sonenberg, N. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2310 · Cited by 933 · cited 1×
“Metformin inhibits phosphorylation of the mTORC1 substrates S6K1 and 4E-BP1 and decreases translation (102).”
BackgroundRapamycin, But Not Resveratrol or Simvastatin, Extends Life Span of Genetically Heterogeneous Mice
Miller, R. A., Harrison, D. E., Astle, C. M., Baur, J. A., Boyd, A. R., de Cabo, R., Fernandez, E., Flurkey, K., Javors, M. A., Nelson, J. F., et al. (2011) · The Journals of Gerontology: Series A · doi:10.1093/gerona/glq178 · Cited by 896 · cited 1×
“study beginning at 9 months of age, rapamycin extended median life span in males and females by 10% and 18%, respectively, and maximum life span by 16% and 13% (23).”
BackgroundSelf-citationJang, Y.-Y., & Sharkis, S. J. (2007) · Blood · doi:10.1182/blood-2007-05-087759 · Cited by 894
Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner
Kalender, A., Selvaraj, A., Kim, S. Y., Gulati, P., Brûlé, S., Viollet, B., Kemp, B. E., Bardeesy, N., Dennis, P., Schlager, J. J., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.03.014 · Cited by 889
Isolation of a Protein Target of the FKBP12-Rapamycin Complex in Mammalian Cells
Sabers, C. J., Martin, M. M., Brunn, G. J., Williams, J. M., Dumont, F. J., Wiederrecht, G., & Abraham, R. T. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.2.815 · Cited by 887
Regulation of Longevity and Stress Resistance by Sch9 in Yeast
Fabrizio, P., Pozza, F., Pletcher, S. D., Gendron, C. M., & Longo, V. D. (2001) · Science · doi:10.1126/science.1059497 · Cited by 874
Bolster, D. R., Crozier, S. J., Kimball, S. R., & Jefferson, L. S. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c200171200 · Cited by 851 · cited 1×
“In fact, this is the case: activation of AMPK by 5-aminoimidazole-4-carboxamide-1β-d-ribonucleoside (AICAR) results in decreased mTORC1 activity (94).”
BackgroundThe mTOR Signalling Pathway in Human Cancer
Pópulo, H., Lopes, J. M., & Soares, P. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13021886 · Cited by 830
Chresta, C. M., Davies, B. R., Hickson, I., Harding, T., Cosulich, S., Critchlow, S. E., Vincent, J. P., Ellston, R., Jones, D., Sini, P., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1751 · Cited by 812
Lifespan extension by conditions that inhibit translation in Caenorhabditis elegans
Hansen, M., Taubert, S., Crawford, D., Libina, N., Lee, S., & Kenyon, C. (2007) · Aging Cell · doi:10.1111/j.1474-9726.2006.00267.x · Cited by 803 · cited 2×
“Interestingly, reducing TOR using RNAi fails to further extend the life spans of eat-2 mutant worms, a model for CR, despite suppressing the already low rate of protein synthesis by an additional 49% (37).”
BackgroundAutophagy and aging: The importance of maintaining "clean" cells
Cuervo, A. M., Bergamini, E., Brunk, U. T., Dröge, W., Ffrench, M., & Terman, A. (2005) · Autophagy · doi:10.4161/auto.1.3.2017 · Cited by 792
A Role for Autophagy in the Extension of Lifespan by Dietary Restriction in C. elegans
Hansen, M., Chandra, A., Mitic, L. L., Onken, B., Driscoll, M., & Kenyon, C. (2008) · PLoS Genetics · doi:10.1371/journal.pgen.0040024 · Cited by 766
mTORC1 in the Paneth cell niche couples intestinal stem-cell function to calorie intake
Yilmaz, Ö. H., Katajisto, P., Lamming, D. W., Gültekin, Y., Bauer-Rowe, K. E., Sengupta, S., Birsoy, K., Dursun, A., Yilmaz, V. O., Selig, M., et al. (2012) · Nature · doi:10.1038/nature11163 · Cited by 753 · cited 2×
“Rapamycin also increases intestinal stem cell selfrenewal via inhibition of mTORC1 in the adjacent Paneth cells, similar to effects that have been in observed in CR animals (65).”
BackgroundResultSelf-citationBrunn, G. J., Williams, J., Sabers, C., Wiederrecht, G., Lawrence, J. C., & Abraham, R. T. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00911.x · Cited by 723
Control of p70 S6 kinase by kinase activity of FRAP in vivo
Brown, E. J., Beal, P. A., Keith, C. T., Chen, J., Bum Shin, T., & Schreiber, S. L. (1995) · Nature · doi:10.1038/377441a0 · Cited by 705
Chen, C., Liu, Y., Liu, R., Ikenoue, T., Guan, K.-L., Liu, Y., & Zheng, P. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20081297 · Cited by 682
mTOR Regulation and Therapeutic Rejuvenation of Aging Hematopoietic Stem Cells
Chen, C., Liu, Y., Liu, Y., & Zheng, P. (2009) · Science Signaling · doi:10.1126/scisignal.2000559 · Cited by 680 · cited 3×
“noted that mTORC1 activity is elevated in HSCs derived from aged mice, which display functional deficits reminiscent of those caused by Tsc1 deletion (25).”
BackgroundOnken, B., & Driscoll, M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008758 · Cited by 671 · cited 1×
“These effects are independent of the insulin signaling pathway but are dependent on AMPK, as well as the oxidative stress transcription factor SKN-1/NRF2 (105).”
BackgroundActivation of mTORC2 by Association with the Ribosome
Zinzalla, V., Stracka, D., Oppliger, W., & Hall, M. N. (2011) · Cell · doi:10.1016/j.cell.2011.02.014 · Cited by 654 · cited 1×
“The regulation of mTORC2 activity is less clear but may involve interaction with ribosomes (10).”
BackgroundTOR Signaling and Rapamycin Influence Longevity by Regulating SKN-1/Nrf and DAF-16/FoxO
Robida-Stubbs, S., Glover-Cutter, K., Lamming, D. W., Mizunuma, M., Narasimhan, S. D., Neumann-Haefelin, E., Sabatini, D. M., & Blackwell, T. K. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.04.007 · Cited by 648 · cited 1×
“elegans suggest that inhibition of mTORC2 can also promote longevity (21, 74).”
BackgroundSelf-citationKume, S., Uzu, T., Horiike, K., Chin-Kanasaki, M., Isshiki, K., Araki, S.-I., Sugimoto, T., Haneda, M., Kashiwagi, A., & Koya, D. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41376 · Cited by 640
IKKβ Suppression of TSC1 Links Inflammation and Tumor Angiogenesis via the mTOR Pathway
Lee, D.-F., Kuo, H.-P., Chen, C.-T., Hsu, J.-M., Chou, C.-K., Wei, Y., Sun, H.-L., Li, L.-Y., Ping, B., Huang, W.-C., et al. (2007) · Cell · doi:10.1016/j.cell.2007.05.058 · Cited by 637
mTOR Is Essential for Growth and Proliferation in Early Mouse Embryos and Embryonic Stem Cells
Murakami, M., Ichisaka, T., Maeda, M., Oshiro, N., Hara, K., Edenhofer, F., Kiyama, H., Yonezawa, K., & Yamanaka, S. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.15.6710-6718.2004 · Cited by 624 · cited 1×
“In mouse embryonic stem cells, expression of pluripotency markers is more resistant to rapamycin treatment, yet cell size and proliferation are still reduced and differentiation is enhanced (67, 69).”
BackgroundWilkinson, J. E., Burmeister, L., Brooks, S. V., Chan, C., Friedline, S., Harrison, D. E., Hejtmancik, J. F., Nadon, N., Strong, R., Wood, L. K., et al. (2012) · Aging Cell · doi:10.1111/j.1474-9726.2012.00832.x · Cited by 619
Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1
Ben Sahra, I., Regazzetti, C., Robert, G., Laurent, K., Le Marchand-Brustel, Y., Auberger, P., Tanti, J.-F., Giorgetti-Peraldi, S., & Bost, F. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1769 · Cited by 616 · cited 1×
“103) and indirectly via upregulation of REDD1, which promotes TSC2 activity (104).”
BackgroundJia, K., Chen, D., & Riddle, D. L. (2004) · Development · doi:10.1242/dev.01255 · Cited by 615
Corradetti, M. N., Inoki, K., Bardeesy, N., DePinho, R. A., & Guan, K.-L. (2004) · Genes & Development · doi:10.1101/gad.1199104 · Cited by 560 · cited 1×
“phorylation of TSC2 and the inhibitory phosphorylation of raptor, an essential component of mTORC1 (92, 93).”
Background4E-BP Extends Lifespan upon Dietary Restriction by Enhancing Mitochondrial Activity in Drosophila
Zid, B. M., Rogers, A. N., Katewa, S. D., Vargas, M. A., Kolipinski, M. C., Lu, T. A., Benzer, S., & Kapahi, P. (2009) · Cell · doi:10.1016/j.cell.2009.07.034 · Cited by 541
Zhang, C., & Cuervo, A. M. (2008) · Nature Medicine · doi:10.1038/nm.1851 · Cited by 520
Inhibition of mRNA translation extends lifespan in Caenorhabditis elegans
Pan, K. Z., Palter, J. E., Rogers, A. N., Olsen, A., Chen, D., Lithgow, G. J., & Kapahi, P. (2007) · Aging Cell · doi:10.1111/j.1474-9726.2006.00266.x · Cited by 498
Drug discovery approaches targeting the PI3K/Akt pathway in cancer
Garcia-Echeverria, C., & Sellers, W. R. (2008) · Oncogene · doi:10.1038/onc.2008.246 · Cited by 473
Yeast Life Span Extension by Depletion of 60S Ribosomal Subunits Is Mediated by Gcn4
Steffen, K. K., MacKay, V. L., Kerr, E. O., Tsuchiya, M., Hu, D., Fox, L. A., Dang, N., Johnston, E. D., Oakes, J. A., Tchao, B. N., et al. (2008) · Cell · doi:10.1016/j.cell.2008.02.037 · Cited by 465 · cited 3×
“Expression of GCN4 is limited by multiple upstream ORFs that normally sequester ribosomes that bind to the mRNA.”
BackgroundInfluentialInhibition of the immune response by rapamycin, a new antifungal antibiotic
Martel, R. R., Klicius, J., & Galet, S. (1977) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y77-007 · Cited by 463 · cited 1×
“In mammals, rapamycin was found to inhibit the immune response and was subsequently adopted as a standard therapy to prevent graft rejection in transplant recipients and to treat autoimmune disorders (2, 3).”
BackgroundRapamycin Attenuates Load-Induced Cardiac Hypertrophy in Mice
Shioi, T., McMullen, J. R., Tarnavski, O., Converso, K., Sherwood, M. C., Manning, W. J., & Izumo, S. (2003) · Circulation · doi:10.1161/01.cir.0000057979.36322.88 · Cited by 462 · cited 1×
“els of cardiac hypertrophy (31, 32) and neurodegenerative diseases (33–35), conditions that affect aging humans.”
BackgroundKu-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)
García-Martínez, J. M., Moran, J., Clarke, R. G., Gray, A., Cosulich, S. C., Chresta, C. M., & Alessi, D. R. (2009) · Biochemical Journal · doi:10.1042/bj20090489 · Cited by 455
Bonawitz, N. D., Chatenay-Lapointe, M., Pan, Y., & Shadel, G. S. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.02.009 · Cited by 422
Din, F. V. N., Valanciute, A., Houde, V. P., Zibrova, D., Green, K. A., Sakamoto, K., Alessi, D. R., & Dunlop, M. G. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.02.050 · Cited by 418 · cited 14×
“We might therefore expect other compounds that activate AMPK to specifically inhibit mTORC1 activity.”
BackgroundInfluentialUnderstanding the benefit of metformin use in cancer treatment
Dowling, R. J., Goodwin, P. J., & Stambolic, V. (2011) · BMC Medicine · doi:10.1186/1741-7015-9-33 · Cited by 409 · cited 1×
“Interestingly, a long-term study in human patients found that treatment with metformin in patients with diabetes decreased mortality from all causes, including diabetesrelated mortality, cancer, and myocardial infarction (108, 109).”
BackgroundAnisimov, V. N., Berstein, L. M., Egormin, P. A., Piskunova, T. S., Popovich, I. G., Zabezhinski, M. A., Kovalenko, I. G., Poroshina, T. E., Semenchenko, A. V., Provinciali, M., et al. (2005) · Experimental Gerontology · doi:10.1016/j.exger.2005.07.007 · Cited by 402 · cited 1×
“Metformin extends the life span of short-lived, tumor-prone HER2/neu mice and female SHR mice (106, 107).”
BackgroundRictor/TORC2 regulates fat metabolism, feeding, growth, and life span in Caenorhabditis elegans
Soukas, A. A., Kane, E. A., Carr, C. E., Melo, J. A., & Ruvkun, G. (2009) · Genes & Development · doi:10.1101/gad.1775409 · Cited by 380 · cited 1×
“elegans suggest that inhibition of mTORC2 can also promote longevity (21, 74).”
BackgroundMcClintock, D., Ratner, D., Lokuge, M., Owens, D. M., Gordon, L. B., Collins, F. S., & Djabali, K. (2007) · PLoS ONE · doi:10.1371/journal.pone.0001269 · Cited by 367 · cited 1×
“org Volume 123 Number 3 March 2013 in smaller amounts during normal cellular aging (59, 60).”
BackgroundThe blooming of the French lilac
Witters, L. A. (2001) · Journal of Clinical Investigation · doi:10.1172/jci14178 · Cited by 367 · cited 1×
“Treatment with metformin lowers blood glucose levels, inhibits lipolysis, and decreases circulating free fatty acids, while producing few undesired side effects (100).”
BackgroundMajumder, S., Richardson, A., Strong, R., & Oddo, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025416 · Cited by 365
Activity of rapamycin (AY-22,989) against transplanted tumors.
ENG, C. P., SEHGAL, S. N., & VEZINA, C. (1984) · The Journal of Antibiotics · doi:10.7164/antibiotics.37.1231 · Cited by 351 · cited 1×
“Rapamycin also broadly inhibits the growth and proliferation of mammalian cells, spurring more recent interest in its use as a cancer therapy (4).”
BackgroundCao, K., Graziotto, J. J., Blair, C. D., Mazzulli, J. R., Erdos, M. R., Krainc, D., & Collins, F. S. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002346 · Cited by 350 · cited 1×
“Gilford progeria, a rare premature aging syndrome (58).”
BackgroundNordihydroguaiaretic acid and aspirin increase lifespan of genetically heterogeneous male mice
Strong, R., Miller, R. A., Astle, C. M., Floyd, R. A., Flurkey, K., Hensley, K. L., Javors, M. A., Leeuwenburgh, C., Nelson, J. F., Ongini, E., et al. (2008) · Aging Cell · doi:10.1111/j.1474-9726.2008.00414.x · Cited by 349 · cited 1×
“Interestingly, aspirin influences longevity in rodent models, extending the average but not maximum life span of male mice (95), and has been found to”
BackgroundMetformin slows down aging and extends life span of female SHR mice
Anisimov, V. N., Berstein, L. M., Egormin, P. A., Piskunova, T. S., Popovich, I. G., Zabezhinski, M. A., Tyndyk, M. L., Yurova, M. V., Kovalenko, I. G., Poroshina, T. E., et al. (2008) · Cell Cycle · doi:10.4161/cc.7.17.6625 · Cited by 348 · cited 1×
“Metformin extends the life span of short-lived, tumor-prone HER2/neu mice and female SHR mice (106, 107).”
BackgroundScreen for Chemical Modulators of Autophagy Reveals Novel Therapeutic Inhibitors of mTORC1 Signaling
Balgi, A. D., Fonseca, B. D., Donohue, E., Tsang, T. C. F., Lajoie, P., Proud, C. G., Nabi, I. R., & Roberge, M. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007124 · Cited by 344 · cited 2×
“Rottlerin regulates mTORC1 in a TSCdependent fashion, but the mechanisms of action for perhexiline, niclosamide, and amiodarone are TSC independent (97).”
BackgroundSteiner, J. P., Connolly, M. A., Valentine, H. L., Hamilton, G. S., Dawson, T. M., Hester, L., & Snyder, S. H. (1997) · Nature Medicine · doi:10.1038/nm0497-421 · Cited by 341
eIF4E function in somatic cells modulates ageing in Caenorhabditis elegans
Syntichaki, P., Troulinaki, K., & Tavernarakis, N. (2007) · Nature · doi:10.1038/nature05603 · Cited by 319 · cited 1×
“the long life spans of worms that lack a key translation initiation factor can still be further increased by TOR deletion, implying that distinct mechanisms are at play (38).”
BackgroundRapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice
Anisimov, V. N., Zabezhinski, M. A., Popovich, I. G., Piskunova, T. S., Semenchenko, A. V., Tyndyk, M. L., Yurova, M. N., Rosenfeld, S. V., & Blagosklonny, M. V. (2011) · Cell Cycle · doi:10.4161/cc.10.24.18486 · Cited by 299 · cited 1×
“However, rapamycin also extends life span in 129/Sv mice, an inbred strain with a more typical life span and tumor incidence (27).”
BackgroundMedvedik, O., Lamming, D. W., Kim, K. D., & Sinclair, D. A. (2007) · PLoS Biology · doi:10.1371/journal.pbio.0050261 · Cited by 275
Self-citationCao, K., Capell, B. C., Erdos, M. R., Djabali, K., & Collins, F. S. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611640104 · Cited by 259 · cited 1×
“org Volume 123 Number 3 March 2013 in smaller amounts during normal cellular aging (59, 60).”
BackgroundGao, Z., Zuberi, A., Quon, M. J., Dong, Z., & Ye, J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300423200 · Cited by 258 · cited 1×
“The most widely used by far is aspirin, which has been shown to decrease S6K phosphorylation in response to TNF-α signaling (89).”
BackgroundRapamycin Extends Maximal Lifespan in Cancer-Prone Mice
Anisimov, V. N., Zabezhinski, M. A., Popovich, I. G., Piskunova, T. S., Semenchenko, A. V., Tyndyk, M. L., Yurova, M. N., Antoch, M. P., & Blagosklonny, M. V. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.091050 · Cited by 257 · cited 1×
“showed that rapamycin extends the maximum life span (mean life span of the last 10% surviving) in a short-lived, tumor-prone strain of mice (FVB/N HER-2/neu transgenic) (26).”
BackgroundLiu, Q., Chang, J. W., Wang, J., Kang, S. A., Thoreen, C. C., Markhard, A., Hur, W., Zhang, J., Sim, T., Sabatini, D. M., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm101144f · Cited by 257
Self-citationAutophagy Regulates Ageing in C. elegans
Hars, E. S., Qi, H., Jin, S. V., Cai, L., Hu, C., & Liu, L. F. (2007) · Autophagy · doi:10.4161/auto.3636 · Cited by 238
Sadoshima, J., & Izumo, S. (1995) · Circulation Research · doi:10.1161/01.res.77.6.1040 · Cited by 229 · cited 1×
“els of cardiac hypertrophy (31, 32) and neurodegenerative diseases (33–35), conditions that affect aging humans.”
BackgroundCutaneous Adverse Events in Renal Transplant Recipients Receiving Sirolimus-Based Therapy1
Mah??, E., Morelon, E., Lechaton, S., Sang, K.-H. L. Q., Mansouri, R., Ducasse, M.-F., Mamzer-Bruneel, M.-F., de Prost, Y., Kreis, H., & Bodemer, C. (2005) · Transplantation · doi:10.1097/01.tp.0000151630.25127.3a · Cited by 228 · cited 4×
“approximately three-fold higher than the typical therapeutic range for immunosuppression in humans (24).”
BackgroundInfluentialHalloran, J., Hussong, S. A., Burbank, R., Podlutskaya, N., Fischer, K. E., Sloane, L. B., Austad, S. N., Strong, R., Richardson, A., Hart, M. J., et al. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.06.054 · Cited by 221 · cited 1×
“tiple age-related changes in mice, including loss of stem cell function (25), cognitive decline (28), retinopathy (29), accumulation of subcellular alterations in the myocardium, liver degeneration, endometrial hyperplasia, tendon stiffening, and decline in physical activity (30).”
Liu, Q., Wang, J., Kang, S. A., Thoreen, C. C., Hur, W., Ahmed, T., Sabatini, D. M., & Gray, N. S. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101520v · Cited by 219
Self-citationYu, K., Shi, C., Toral-Barza, L., Lucas, J., Shor, B., Kim, J. E., Zhang, W.-G., Mahoney, R., Gaydos, C., Tardio, L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2340 · Cited by 206
Chen, T., Shen, L., Yu, J., Wan, H., Guo, A., Chen, J., Long, Y., Zhao, J., & Pei, G. (2011) · Aging Cell · doi:10.1111/j.1474-9726.2011.00722.x · Cited by 204 · cited 1×
“addition, rapamycin enhances the reprogramming of somatic cells to generate induced pluripotent stem cells, suggesting a general promotion of stem cell function (66).”
BackgroundmTORC1-dependent and -independent regulation of stem cell renewal, differentiation, and mobilization
Gan, B., Sahin, E., Jiang, S., Sanchez-Aguilera, A., Scott, K. L., Chin, L., Williams, D. A., Kwiatkowski, D. J., & DePinho, R. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810584105 · Cited by 204
Zhou, J., Su, P., Wang, L., Chen, J., Zimmermann, M., Genbacev, O., Afonja, O., Horne, M. C., Tanaka, T., Duan, E., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0901854106 · Cited by 204 · cited 2×
“In mouse embryonic stem cells, expression of pluripotency markers is more resistant to rapamycin treatment, yet cell size and proliferation are still reduced and differentiation is enhanced (67, 69).”
BackgroundCaffeine extends yeast lifespan by targeting TORC1
Wanke, V., Cameroni, E., Uotila, A., Piccolis, M., Urban, J., Loewith, R., & De Virgilio, C. (2008) · Molecular Microbiology · doi:10.1111/j.1365-2958.2008.06292.x · Cited by 201 · cited 1×
“be sufficient to have a mild effect on mTOR in humans (87).”
BackgroundBhagwat, S. V., Gokhale, P. C., Crew, A. P., Cooke, A., Yao, Y., Mantis, C., Kahler, J., Workman, J., Bittner, M., Dudkin, L., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-1099 · Cited by 198 · cited 1×
“The IC50 for OSI-027 against mTORC2 is 65 nM, approximately 3-fold higher than the IC50 against mTORC1 (124).”
BackgroundFabrizio, P., Pletcher, S. D., Minois, N., Vaupel, J. W., & Longo, V. D. (2004) · FEBS Letters · doi:10.1016/s0014-5793(03)01462-5 · Cited by 189
Autophagy is required for extension of yeast chronological life span by rapamycin
Alvers, A. L., Wood, M. S., Hu, D., Kaywell, A. C., Dunn, Jr., & Aris, J. P. (2009) · Autophagy · doi:10.4161/auto.8824 · Cited by 189
Shor, B., Wu, J., Shakey, Q., Toral-Barza, L., Shi, C., Follettie, M., & Yu, K. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.071639 · Cited by 182 · cited 1×
“in particular have revealed important but previously unknown biological mechanisms, including rapamycin-resistant functions of mTORC1 (85, 86).”
BackgroundHua, Y., Zhang, Y., Ceylan-Isik, A. F., Wold, L. E., Nunn, J. M., & Ren, J. (2011) · Basic Research in Cardiology · doi:10.1007/s00395-011-0222-8 · Cited by 178 · cited 1×
“Cardiomyocytes isolated from aged mice have lower autophagy and exhibit defects in calcium handling, both of which are corrected by exposure to rapamycin ex vivo (56).”
BackgroundActivated FOXO-mediated insulin resistance is blocked by reduction of TOR activity
Luong, N., Davies, C. R., Wessells, R. J., Graham, S. M., King, M. T., Veech, R., Bodmer, R., & Oldham, S. M. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.05.013 · Cited by 174
Lee, K.-W., Yook, J.-Y., Son, M.-Y., Kim, M.-J., Koo, D.-B., Han, Y.-M., & Cho, Y. S. (2010) · Stem Cells and Development · doi:10.1089/scd.2009.0147 · Cited by 163 · cited 1×
“cin impairs pluripotency, reduces proliferation, and promotes differentiation in human embryonic stem cells (67, 68).”
BackgroundPremature aging in mice activates a systemic metabolic response involving autophagy induction
Mariño, G., Ugalde, A. P., Salvador-Montoliu, N., Varela, I., Quirós, P. M., Cadiñanos, J., van der Pluijm, I., Freije, J. M. P., & López-Otín, C. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn120 · Cited by 159 · cited 1×
“pro-aging phenotype of progeroid mice (57).”
Sirolimus May Reduce Fertility in Male Renal Transplant Recipients
Zuber, J., Anglicheau, D., Elie, C., Bererhi, L., Timsit, M.-O., Mamzer-Bruneel, M.-F., Ciroldi, M., Martinez, F., Snanoudj, R., Hiesse, C., et al. (2008) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2008.02267.x · Cited by 148 · cited 1×
“Rapamycin treatment has been associated with hair and nail disorders, with 90% of patients experiencing alopecia (24), and with loss of testicular function and reduced male fertility in both humans and mice (30, 81).”
BackgroundAraki, K., Ellebedy, A. H., & Ahmed, R. (2011) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2011.08.006 · Cited by 146 · cited 1×
“A complete discussion of the immunological effects of rapamycin is beyond the scope of this Review, and the topic has been covered elsewhere (72).”
BackgroundN-acylethanolamine signalling mediates the effect of diet on lifespan in Caenorhabditis elegans
Lucanic, M., Held, J. M., Vantipalli, M. C., Klang, I. M., Graham, J. B., Gibson, B. W., Lithgow, G. J., & Gill, M. S. (2011) · Nature · doi:10.1038/nature10007 · Cited by 142
Management of Side Effects of Sirolimus Therapy
Stallone, G., Infante, B., Grandaliano, G., & Gesualdo, L. (2009) · Transplantation · doi:10.1097/tp.0b013e3181a05b7a · Cited by 131 · cited 1×
“Cancer and transplant patients are willing to tolerate these side effects as well as anemia, renal toxicity, impaired wound healing, and joint pain because the benefits outweigh the risks (83).”
BackgroundTargeting Melanoma with Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors
Marone, R., Erhart, D., Mertz, A. C., Bohnacker, T., Schnell, C., Cmiljanović, V., Stauffer, F., García-Echeverría, C., Giese, B., Maira, S.-M., et al. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0366 · Cited by 119
Ruan, B. H., Pong, K., Jow, F., Bowlby, M. R., Crozier, R. A., Liu, D., Shi, L., Chen, Y., Mercado, M. L. T., Feng, X., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710424105 · Cited by 112
Mieulet, V., Roceri, M., Espeillac, C., Sotiropoulos, A., Ohanna, M., Oorschot, V., Klumperman, J., Sandri, M., & Pende, M. (2007) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00499.2006 · Cited by 99 · cited 1×
“While female mice lacking S6K1 have extended life spans, there is no discernible effect on overall translation, at least in skeletal muscle (41).”
BackgroundGreenberger, S., Yuan, S., Walsh, L. A., Boscolo, E., Kang, K.-T., Matthews, B., Mulliken, J. B., & Bischoff, J. (2011) · Journal of Investigative Dermatology · doi:10.1038/jid.2011.300 · Cited by 94 · cited 1×
“rapamycin depletes leukemia-initiating cells and inhibits both the self-renewal and differentiation capacities of stem cells derived from infantile hemangioma, suggesting a protective effect against cancer stem cells (61, 70).”
Prevention of Age-Related Macular Degeneration–Like Retinopathy by Rapamycin in Rats
Kolosova, N. G., Muraleva, N. A., Александровна, Ж. А., Stefanova, N. A., Фурсова, А. Ж., & Blagosklonny, M. V. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.04.018 · Cited by 82
Ha, C. W., & Huh, W.-K. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq895 · Cited by 77
On why decreasing protein synthesis can increase lifespan
Hipkiss, A. R. (2007) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2007.03.002 · Cited by 72 · cited 1×
“org Volume 123 Number 3 March 2013 or damaged proteins (36).”
BackgroundGyürüs, É., Kaposztas, Z., & Kahan, B. D. (2011) · Transplantation Proceedings · doi:10.1016/j.transproceed.2011.05.001 · Cited by 71 · cited 1×
“In addition, rapamycin treatment leads to metabolic changes, including hyperlipidemia, decreased insulin sensitivity, glucose intolerance, and an increased incidence of new-onset diabetes (79, 82).”
BackgroundImproving survival with metformin: the evidence base today
Scarpello, J. H. B. (2003) · Diabetes & Metabolism · doi:10.1016/s1262-3636(03)72786-4 · Cited by 71 · cited 1×
“Interestingly, a long-term study in human patients found that treatment with metformin in patients with diabetes decreased mortality from all causes, including diabetesrelated mortality, cancer, and myocardial infarction (108, 109).”
BackgroundAutophagy and ageing: Insights from invertebrate model organisms
Lionaki, E., Markaki, M., & Tavernarakis, N. (2013) · Ageing Research Reviews · doi:10.1016/j.arr.2012.05.001 · Cited by 61
Sirolimus: Continuing the Evolution of Transplant Immunosuppression
Ingle, G. R., Sievers, T. M., & Holt, C. (2000) · Annals of Pharmacotherapy · doi:10.1345/aph.19380 · Cited by 57 · cited 1×
“In mammals, rapamycin was found to inhibit the immune response and was subsequently adopted as a standard therapy to prevent graft rejection in transplant recipients and to treat autoimmune disorders (2, 3).”
BackgroundHan, X., Turdi, S., Hu, N., Guo, R., Zhang, Y., & Ren, J. (2012) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2011.11.002 · Cited by 56
Sun, X., Komatsu, T., Lim, J., Laslo, M., Yolitz, J., Wang, C., Poirier, L., Alberico, T., & Zou, S. (2012) · Aging Cell · doi:10.1111/j.1474-9726.2012.00842.x · Cited by 50
Wang, M., & Miller, R. A. (2012) · Aging Cell · doi:10.1111/j.1474-9726.2012.00833.x · Cited by 45 · cited 1×
“dwarf mice also show evidence of increased autophagy (55).”
BackgroundHegde, S. G., & Schmidt, M. A. (2005) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(05)40029-9 · Cited by 45
Distinct Repression of Translation by Wortmannin and Rapamycin
Pedersen, S., Celis, J. E., Nielsen, J., Christiansen, J., & Nielsen, F. C. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.00449.x · Cited by 36 · cited 1×
“complete loss of mTOR function has a major effect on general translation, rapamycin has a more subtle effect, most likely because a subset of the functions of 4E-BP is rapamycin resistant (42, 43).”
BackgroundCavell, B. E., Alwi, S. S. S., Donlevy, A. M., Proud, C. G., & Packham, G. (2012) · Journal of Natural Products · doi:10.1021/np300049b · Cited by 32 · cited 1×
“shown to inhibit mTORC1 activity in a TSC-dependent manner (98).”
BackgroundEffect of rapamycin on lifespan in Drosophila
Harrison, B. R., Tran, T. T., Taylor, D., Lee, S., & Min, K. (2009) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/j.1447-0594.2009.00569.x · Cited by 25
Chen, Z., Li, Z., Wei, B., Yin, W., Xu, T., Kotlikoff, M. I., & Ji, G. (2009) · The FASEB Journal · doi:10.1096/fj.09-138446 · Cited by 23 · cited 1×
“tiple excitable cell types, in part through binding to ryanodine receptors (75, 76).”
BackgroundDuthois, S., Cailleux, N., Benosman, B., & Levesque, H. (2003) · Diabetes & Metabolism · doi:10.1016/s1262-3636(07)70005-8 · Cited by 21
A new tool to dissect the function of p70 S6 kinase
Bilanges, B., & Vanhaesebroeck, B. (2010) · Biochemical Journal · doi:10.1042/bj20101445 · Cited by 16 · cited 1×
“org Volume 123 Number 3 March 2013 inhibitors are now being developed (88), but even if sufficient selectivity is achieved, these compounds will require many years of development before FDA approval.”
BackgroundThe Role of FK506-Binding Proteins 12 and 12.6 in Regulating Cardiac Function
Li, B., Chen, H., Maruyama, M., Zhang, W., Zhang, J., Pan, Z., Rubart, M., Chen, P., & Shou, W. (2012) · Pediatric Cardiology · doi:10.1007/s00246-012-0298-4 · Cited by 7 · cited 1×
“tiple excitable cell types, in part through binding to ryanodine receptors (75, 76).”
Background
Cited by
Mechanism and medical implications of mammalian autophagy
Dikic, I., & Elazar, Z. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0003-4 · Cited by 2,771
MTOR: a pharmacologic target for autophagy regulation
Kim, Y. C., & Guan, K.-L. (2015) · Journal of Clinical Investigation · doi:10.1172/jci73939 · Cited by 2,126
Rapamycin: one drug, many effects
Li, J., Kim, S. G., & Blenis, J. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.01.001 · Cited by 1,287
Cellular senescence and senolytics: the path to the clinic
Chaib, S., Tchkonia, T., & Kirkland, J. L. (2022) · Nature Medicine · doi:10.1038/s41591-022-01923-y · Cited by 1,134
Mills, K. F., Yoshida, S., Stein, L. R., Grozio, A., Kubota, S., Sasaki, Y., Redpath, P., Migaud, M. E., Apte, R. S., Uchida, K., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.09.013 · Cited by 930
“Ce aging healthy and prevent expensive age-associated health problems, efforts to develop effective, affordable, anti-aging interventions have recently been intensified, leading to some promising compounds, such as metformin, rapamycin, and SIRT1 activators (Barzilai et al., 2016; Hubbard and Sinclair, 2014; Lamming e…”
Metadata
- Authors
- Lamming, D. W., Ye, L., Sabatini, D. M., & Baur, J. A.
- Affiliations
- Howard Hughes Medical Institute (US)
- University of Pennsylvania (US)
- Broad Institute (US)
- Corresponding author
- Baur, Joseph A.
- Venue
- Journal of Clinical Investigation
- Published
- 2013-03-01
- Volume
- 123
- Issue
- 3
- Pages
- 980-989
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3582126
- OpenAlex
- W2129902630
- Cited by
- 531
- References
- 133
- Citations by year
- 2026: 18 · 2025: 32 · 2024: 42 · 2023: 37 · 2022: 41 · 2021: 25 · 2020: 28 · 2019: 44 · 2018: 46 · 2017: 38 · 2016: 57 · 2015: 61 · 2014: 46 · 2013: 16
- FWCI
- 3.69
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Howard Hughes Medical Institute
- Ellison Medical Foundation
- American Federation for Aging Research
- American Heart Association
- Charles A. King Trust
- Starr Foundation
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
- National Institutes of Health
- National Institute on Aging (K99AG041765)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
- Keywords
- rapamycin, rapalogs, mTOR inhibitors, anti-aging therapeutics, longevity, lifespan extension, mTOR signaling, genetically heterogeneous mice, adverse drug reactions
- MeSH terms
- Aging, Animals, Anti-Inflammatory Agents, Antineoplastic Agents, Autophagy, Humans, Metformin, Neoplasms, Stem Cells, Sirolimus, TOR Serine-Threonine Kinases, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.